Apnimed Inc: A clinical-stage company innovating pharmacologic therapies for sleep disorders in Massachusetts.
Founded in Massachusetts, Apnimed Inc is a clinical-stage company dedicated to the discovery and development of novel pharmacologic therapies for sleep apnea and related disorders. The company's core mission is to transform the treatment of sleep disorders through innovative drug therapies, aiming to improve patient outcomes and quality of life. Apnimed's primary focus is on obstructive sleep apnea (OSA), and its leading product candidate, AD109, is currently in Phase 3 clinical trials.
Apnimed has garnered recognition for its groundbreaking research and has been named one of the best places to work by the Boston Business Journal. The company boasts a strong team of experts and advisors in the fields of sleep medicine and pharmacology. Apnimed's achievements include advancing its lead candidate through significant clinical milestones, positioning it as a potential game-changer in the treatment of OSA. The company's impact lies in its innovative approach to addressing unmet medical needs in sleep disorders.

Apnicure
apnicure.com

Apnex Medical

Somnea Health
somnea.co

RespireRx Pharmaceuticals
respirerx.com

ResMed
resmed.com

Lunosa

XII Medical
xiimedical.com

StimAire
stimaire.com

Invicta Medical

Airing
fundairing.com

Sommetrics
sommetrics.com

Appian Medical
appianmed.com

Cryosa
cryosa.com

Somnus Therapeutics
somnusthera.com
Anapneo Therapeutics
Companies similar to Apnimed include Apnicure, Apnex Medical, Somnea Health and RespireRx Pharmaceuticals.
Apnimed was founded in 2017.
Apnimed's headquarters is located in Cambridge, MA, US.
Apnimed's most recent funding round was for $79.7M (USD) in December 2022.
As of Dec 23, 2022, Apnimed has raised a total of $207.8M (USD).
Apnimed has 29 employees as of Feb 5, 2024.